54 results
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
significant market acceptance among physicians, patients and healthcare payors;
our ability to maintain regulatory approval of KIMMTRAK for metastatic … countries, including potential changes in healthcare laws and regulations;
our financial performance and our ability to effectively manage our anticipated
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
believe his extensive scientific background and experience in the healthcare industry qualify him to serve on our board of directors.
Vote Required … previously served as a senior advisor to the Healthcare Businesswomen’s Association and a Member of the Biotechnology Industry Organization Board. Ms
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
ability to continue to generate revenues, which is dependent upon maintaining significant market acceptance among physicians, patients and healthcare … and other countries, including potential changes in healthcare laws and regulations;
our financial performance and our ability to effectively manage
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
sciences industry. We believe his extensive scientific background and experience in the healthcare industry qualify him to serve on our board of directors … . Additionally, she previously served as a senior advisor to the Healthcare Businesswomen’s Association and a Member of the Biotechnology Industry
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
, patients and healthcare payors;
our ability to maintain regulatory approval of KIMMTRAK for metastatic uveal melanoma, or mUM, in the United States … in the United States and other countries, including potential changes in healthcare laws and regulations;
our financial performance and our ability
10-K
4j9f3
28 Feb 24
Annual report
7:33am
8-K
EX-99.1
a7jt06gaa9cz2vp9s
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
8-K
sm1gey4i
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.2
ai6q02i 8z4zp29m
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
juvvo
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
v0v5c8ohbcl g4k0
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.3
4sckstyx
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.1
fxpsu
18 Apr 23
Current report (foreign)
4:13pm
6-K/A
EX-99.1
iqi26w tb
18 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
4:17pm
6-K
EX-99.2
cd4wz5wa4nrqat
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.1
73ouxsxw2r4u1
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.4
hg06n p2161ngbbn
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
at7b5c2vzkf
30 Sep 22
Prospectus with selling stockholder info
4:15pm
424B5
dy0hqqgtjyvjj5qgs4
9 Sep 22
Prospectus supplement for primary offering
4:23pm
6-K
EX-99.3
rt5l705e3mjtpaf1yo
10 Aug 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
8:00am